Preferential share issue: additional disclosures on timing and ownership
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On 4 November 2026, Gujarat Themis Biosyn said shareholders had approved a preferential share issue on 30 September 2026. It clarified a 12-month proceeds-use period from share allotment, named the ultimate owners of three proposed investors and posted a company secretary certificate. Exchange approval is pending; issue terms are unchanged.
The proposed terms are unchanged. Shareholders may face dilution once new shares are allotted; no issue price is stated in this filing.